Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Staghorn69on Jun 14, 2017 9:03am
208 Views
Post# 26360313

RE:RE:PLI - FDA discussion

RE:RE:PLI - FDA discussion
Aureus wrote: FDA is not about to render an approval decision. At this point, they have to decide what kind of review they will assign to PLI. How complicated can that be? So the extra questioning and possible related delay has to do with PR review vs standard and a possible voucher. In that context, one would hope that this extra questioning means that this is not going to be just a standard 10 months review, otherwise you would think that they would have rendered their decision already. In hoping that they are asking more questions before giving away a Priority review (after all, they have to substantiate why we would be reviewed in 6 months ahead of others), or even better, more questions before giving away a very rare and valuable voucher. Fingers crossed !


Not to sound like a raging pumper, I DO think it is POSSIBLE for the FDA to give an early conditional approval in the case of Pg. They were going through a rolling BLA where they were presumably in contact with the FDA often, PLUS look at what we are dealing with here?? Plasminogen is already produced in all of us, unfortunately in lower amounts in others with noted conditions. This is not some chemical mixture that cures X but also makes you impotent and grow hair where you don't want it - Pg is produced in the human body so extremely safe and tolerable. If there's ever been a candidate for a conditional approval at this stage this is it...

Now I'd agree the likelihood of that hovers somewhere around zero. I'd agree it is puzzling to see a delay in the process to DECIDE what KIND of review they get, particularly again since there was a rolling BLA and you'd think regular contact with FDA about how to file the BLA.
Bullboard Posts